Get the Stockscreener App
3.06
2.68%
0.08
Pre-market:
3.04
-0.02
-0.65%
Chemomab Therapeutics Ltd Adr stock is traded at $3.06, with a volume of 52,548.
It is up +2.68% in the last 24 hours and up +16.35% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
See More
Previous Close:
$2.98
Open:
$3.06
24h Volume:
52,548
Relative Volume:
0.28
Market Cap:
$15.83M
Revenue:
-
Net Income/Loss:
$-33.08M
P/E Ratio:
-1.0408
EPS:
-2.94
Net Cash Flow:
$-25.68M
1W Performance:
-5.85%
1M Performance:
+16.35%
6M Performance:
+126.67%
1Y Performance:
+115.49%
1-Day Range:
$3.01
$3.10
1-Week Range:
$2.95
$3.4399
52-Week Range:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
3.06 | 15.47M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-24 | Initiated | Maxim Group | Buy |
| May-06-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-19-23 | Resumed | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
Oppenheimer raises Chemomab stock price target to $25 on M&A potential By Investing.com - Investing.com South Africa
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com Nigeria
Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer - TipRanks
CMMB’s Market Whiplash: -34.81% YTD Decline, -15.11% Plunge in 30 Days - investchronicle.com
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy - sharewise
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Chemomab prepares for annual shareholder meeting By Investing.com - Investing.com India
Chemomab prepares for annual shareholder meeting - Investing.com
Chemomab Leadership Changes Signal Strategic Momentum Following Positive Clinical Results - Barchart.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Microsoft Stock After Xbox Price Hike: Buy Or Hold? - Barchart.com
Should You Buy, Sell, Or Hold Nio Stock Amid Firefly Brand Launch? - Barchart.com
UBS Group Q1 Earnings & Revenues Dip Y/Y, Credit Loss Expenses Slip - Barchart.com
This ‘Strong Buy’ Robotaxi Stock Just Got A Huge Bump. Should You Buy Shares Now? - Barchart.com
Chemomab reports promising PSC treatment data - Investing.com
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):